Overt Diabetes in Pregnancy Diagnosis and Management

Diagnostic Criteria

• The American Diabetes Association recommends an OGTT value of ≥200 mg/dL on any glucose measurement during OGTT for the diagnosis of overt diabetes 1
• The American Diabetes Association confirms overt diabetes with an HbA1c of ≥6.5% for diabetes diagnosis 2, 3, 1
• Both tests being above diagnostic thresholds confirms the diagnosis without need for repeat testing, according to the American Diabetes Association 2

Clinical Implications

• Women with overt diabetes in pregnancy have substantially higher risks for adverse maternal and fetal outcomes compared to GDM, including major congenital malformations if hyperglycemia was present during organogenesis, as stated by the American Diabetes Association 1
• More aggressive management is required than for typical GDM, according to the American Diabetes Association 4, 5

Management Approach

• Insulin therapy should be initiated immediately as this degree of hyperglycemia will not be controlled with lifestyle modifications alone, recommends the American Diabetes Association 4, 5, 6
• Target fasting glucose <95 mg/dL, target 1-hour postprandial <140 mg/dL, and target 2-hour postprandial <120 mg/dL, as recommended by the American Diabetes Association 4, 5, 6
• Self-monitoring of blood glucose should be performed preprandially and postprandially, according to the American Diabetes Association 4, 6
• HbA1c should be monitored monthly during pregnancy due to altered red blood cell kinetics, recommends the American Diabetes Association 4, 5, 6
• Target HbA1c of 6-6.5%, with <6% optimal as pregnancy progresses if achievable without hypoglycemia, as stated by the American Diabetes Association 4, 5, 6

Medical Nutrition Therapy

• Immediate nutritional counseling with a registered dietitian is essential, recommends the American Diabetes Association 4, 6
• Minimum 175 g carbohydrate daily, minimum 71 g protein daily, and 28 g fiber daily, as recommended by the American Diabetes Association 4, 6

Fetal Surveillance

• Enhanced obstetric monitoring is required given the significantly elevated glucose levels, according to the American Diabetes Association 7
• Regular ultrasounds to assess fetal growth and detect macrosomia, monitoring for polyhydramnios, and assessment for congenital anomalies, recommends the American Diabetes Association 7

Postpartum Considerations

• This patient will require postpartum glucose testing at 4-12 weeks with a 75-g OGTT using non-pregnant diagnostic criteria to determine if diabetes persists, as recommended by the American Diabetes Association 7
• Lifelong screening for diabetes at least every 3 years will be necessary, according to the American Diabetes Association 7

Management of Overt Diabetes in Pregnancy

Diagnosis and Treatment

• The American Diabetes Association recommends insulin as the preferred and first-line medication for treating hyperglycemia in pregnancy, as metformin and glyburide should not be used as first-line agents due to concerns about their safety for the fetus 8, 9
• Insulin requirements typically increase linearly by 5% per week from week 16 through week 36, often resulting in doubling of daily insulin dose compared to pre-pregnancy requirements 10
• The patient will likely require substantial insulin doses given the severity of hyperglycemia at presentation 11

Glycemic Targets and Monitoring

• Target blood glucose levels are fasting glucose: 70-95 mg/dL, one-hour postprandial: 110-140 mg/dL, and two-hour postprandial: 100-120 mg/dL through intensive insulin therapy and self-monitoring 11, 8
• Target HbA1c of 6-6.5%, with <6% optimal as pregnancy progresses if achievable without significant hypoglycemia, and monitor HbA1c monthly during pregnancy 11
• Postprandial monitoring is associated with better glycemic control and lower risk of preeclampsia 11, 10

Medical Nutrition Therapy and Insulin Adjustment

• Consistent carbohydrate intake is critical to match insulin administration 12
• Insulin adjustment should be made every 3-4 days until self-monitored blood glucose targets are reached, with consideration of progressive dose escalation due to increasing insulin resistance 10, 12

Blood Glucose Monitoring and Continuous Glucose Monitoring

• Perform self-monitoring of blood glucose both preprandially and postprandially, and consider continuous glucose monitoring (CGM) if available, with target range of 63-140 mg/dL and goal of >70% time in range 11, 8

A1C Targets in Pregnancy

Optimal Target and Rationale

• The American Diabetes Association recommends an ideal A1C goal of <6% (42 mmol/mol) throughout pregnancy, as this level is associated with the lowest rates of adverse fetal outcomes, including large-for-gestational-age infants, preterm delivery, and preeclampsia 13
• A1C levels are physiologically lower in normal pregnancy due to increased red blood cell turnover, making the normal pregnancy A1C range naturally lower than in non-pregnant individuals, according to the American Diabetes Association 14, 15, 16
• A1C <6% has been shown to have the lowest risk of macrosomia, preterm delivery, and preeclampsia in observational studies, as stated by the American Diabetes Association 13

Individualization Based on Hypoglycemia Risk

• If the <6% target cannot be achieved safely without significant hypoglycemia, the American Diabetes Association recommends relaxing the target to <7% (53 mmol/mol) 15, 16, 13
• Hypoglycemia during pregnancy carries additional risks beyond the usual adverse effects, including potential increased risk of low birth weight, making it critical to balance tight control against hypoglycemia risk, as noted by the American Diabetes Association 13

Preconception A1C Target

• The American Diabetes Association recommends a preconception A1C target of <7% to minimize the risk of congenital anomalies, spontaneous abortion, and diabetic embryopathy (including anencephaly, microcephaly, and congenital heart disease) 14

Monitoring Frequency

• A1C should be monitored more frequently during pregnancy than in non-pregnant individuals (e.g., monthly) due to altered red blood cell kinetics and the need for close glycemic surveillance, as recommended by the American Diabetes Association 15, 13

Important Caveats

• A1C should be used as a secondary measure of glycemic control in pregnancy, not the primary metric, because it may not fully capture postprandial hyperglycemia which drives macrosomia, according to the American Diabetes Association 13
• Self-monitoring of blood glucose (fasting and postprandial) remains the primary method for achieving optimal glycemic control during pregnancy, with targets of fasting 70-95 mg/dL (3.9-5.3 mmol/L), 1-hour postprandial 110-140 mg/dL (6.1-7.8 mmol/L), or 2-hour postprandial 100-120 mg/dL (5.6-6.7 mmol/L), as recommended by the American Diabetes Association 13

Management of Elevated A1C in Pregestational Diabetes During Pregnancy

Immediate Insulin Management

• Initiate or intensify insulin therapy promptly to achieve an A1C < 6 % (ideal) or < 6.5 % (maximum) to markedly reduce the risk of congenital anomalies, preeclampsia, macrosomia, and perinatal mortality. 17
• Insulin is the mandatory first‑line pharmacologic agent for pregestational diabetes in pregnancy and must be started or intensified immediately when A1C is elevated. [18][17]
• Employ a basal‑bolus regimen using NPH or long‑acting insulin for basal coverage plus rapid‑acting insulin analogs before meals. [18][17]
• Anticipate a linear increase in insulin requirements of about 5 % per week from gestational week 16 through week 36, often resulting in a total daily dose that is roughly double the pre‑pregnancy dose. 17
• Do not use metformin or glyburide as first‑line agents for pregestational diabetes; they are reserved only for gestational diabetes when insulin cannot be used. 18

Glycemic Targets

• Target fasting glucose 70–95 mg/dL (3.9–5.3 mmol/L); 1‑hour post‑prandial 110–140 mg/dL (6.1–7.8 mmol/L); 2‑hour post‑prandial 100–120 mg/dL (5.6–6.7 mmol/L). 17
• A1C goals:
  
  • Optimal: < 6 % (42 mmol/mol) if achievable without significant hypoglycemia.
  • Acceptable: 6–6.5 % (42–48 mmol/mol).
  • Maximum acceptable: < 7 % (53 mmol/mol) only when lower targets provoke recurrent severe hypoglycemia. 17

Self‑Monitoring & Continuous Glucose Monitoring

• Perform blood‑glucose checks 4–7 times daily (pre‑meal and 1–2 h post‑meal). This frequency is linked to better glycemic control and a lower risk of preeclampsia. 17
• When available, use continuous glucose monitoring (CGM) aiming for > 70 % time‑in‑range (63–140 mg/dL); CGM use reduces large‑for‑gestational‑age births, neonatal hypoglycemia, and NICU admissions in type 1 diabetes. 17

A1C Monitoring Frequency

• Measure A1C monthly throughout pregnancy (rather than quarterly) because altered red‑cell kinetics demand close surveillance. [18][17]
• Treat A1C as a secondary metric; self‑monitored glucose remains primary because A1C may miss post‑prandial spikes that drive macrosomia. [18][17]

Medical Nutrition Therapy

• Refer promptly to a registered dietitian for individualized meal planning. [18][17]
• Ensure consistent carbohydrate intake at each meal to align with insulin dosing and prevent both hyper‑ and hypoglycemia. [18][17]

Medication Review & Safety

• Discontinue teratogenic medications immediately, including ACE inhibitors, ARBs (linked to fetal renal anomalies, oligohydramnios, fetal death) and statins (pregnancy category X). 19

Multidisciplinary Care & Fetal Surveillance

• Provide dilated eye examinations each trimester to monitor for retinopathy progression. 19
• Conduct targeted fetal surveillance for congenital anomalies—especially cardiac and neural‑tube defects—if A1C was elevated during organogenesis (weeks 5–8). 19

Hypoglycemia Prevention & Target Adjustment

• Balance aggressive glucose control against hypoglycemia risk, recognizing that hypoglycemia can increase the chance of low birth weight. [18][17]
• In patients with type 1 diabetes and a history of recurrent hypoglycemia or hypoglycemia unawareness, adopt the less stringent A1C target of < 7 % rather than < 6 %. [18][17]